Combining Anti-TNF-Alpha Therapy with Enzyme Replacement Therapy in MPS VI Rats
Author Information
Author(s): Eliyahu Efrat, Wolfson Theodore, Ge Yi, Jepsen Karl J., Schuchman Edward H., Simonaro Calogera M.
Primary Institution: Mount Sinai School of Medicine, New York, New York, United States of America
Hypothesis
Does combining anti-TNF-alpha therapy with enzyme replacement therapy provide additional benefits in treating MPS VI rats?
Conclusion
The study found that combining anti-TNF-alpha therapy with enzyme replacement therapy improved treatment outcomes in MPS VI rats.
Supporting Evidence
- Both treatment protocols led to significantly reduced serum levels of TNF-alpha and RANKL.
- Motor activity and mobility were improved by enzyme replacement therapy, significantly enhanced by combination treatment.
- Tracheal deformities in MPS VI animals were only improved by combination therapy.
Takeaway
Researchers tested a new treatment for sick rats and found that using two medicines together helped them feel better than just one medicine alone.
Methodology
MPS VI rats were treated for 8 months with either enzyme replacement therapy or a combination of enzyme replacement therapy and anti-TNF-alpha therapy, followed by various analyses.
Potential Biases
Potential bias due to the lack of a control group for anti-TNF-alpha therapy alone.
Limitations
The study did not include a group treated with anti-TNF-alpha therapy alone, limiting the ability to isolate the effects of the combination treatment.
Participant Demographics
MPS VI rats, aged 21 days at the start of treatment.
Statistical Information
P-Value
p<0.005
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website